Medicare Part D coverage · carbidopa · RxCUI 2690265

carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]

Per the CMS 2026 Part D formulary file, carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] is covered by 6 Medicare Part D plans (0.1% of enrollable products), averaging Tier 2.5, with prior authorization required on 0% of covering formularies.

0.1%
Plan coverage
6
Plans covering
T2.5
Avg tier
0%
Prior auth required

Verify with CMS →

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.

What the CMS Formulary Data Shows for carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]

Per the CMS 2026 Part D formulary file, carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] (RxNorm concept RXCUI 2690265, generic name carbidopa) appears on 4 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.5.

Real-world access to carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 4,842 Part D beneficiaries filled carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] in 2023, with total plan-and-beneficiary spending of $8,583,589 and an average per-beneficiary annual cost of $1,772.74. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] today.

Coverage Details

Formularies covering
4
Plans covering
6
Coverage rate
0.1%
Tier range
Tier 1 – Tier 4
Average tier
Tier 3, Preferred Brand

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
4,842
Total spending
$8,583,589
Avg per beneficiary
$1,772.74

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic
4 plans
Tier 4, Non-Preferred

Medicare Advantage Plans (MA-PD) Covering carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]

6 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Mass General Brigham SCO (HMO D-SNP) Mass General Brigham Health Plan, Inc T1 No $0 MA
Mass General Brigham One Care (HMO D-SNP) Mass General Brigham Health Plan, Inc T1 No $0 MA
Mass General Brigham Advantage (PPO) Mass General Brigham Health Plan, Inc. T4 No $0 MA
Mass General Brigham Advantage Secure (HMO-POS) Mass General Brigham Health Plan, Inc. T4 No $62.00 MA
Mass General Brigham Advantage Premier (PPO) Mass General Brigham Health Plan, Inc. T4 No $79.70 MA
Mass General Brigham Advantage Signature (PPO) Mass General Brigham Health Plan, Inc. T4 No $147.20 MA

Frequently Asked Questions

Is carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] covered by Medicare Part D?

Yes, carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).

What tier is carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] on Medicare Part D plans?

carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 4.

Does carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] require prior authorization?

0% of Part D formularies require prior authorization for carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont]?

In 2023, total Medicare Part D spending on carbidopa 35 MG / levodopa 140 MG Extended Release Oral Capsule [Crexont] was $8,583,589, covering 4,842 beneficiaries. The average spend per beneficiary was $1,772.74.

Read our methodology - how this data is sourced, computed, and verified.

Nationwide similar Part D drugs

Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.

Closest average formulary tier

Similar prior-authorization rate

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare